ATE468109T1 - Liposomale abgabe von verbindungen auf vitamin-e- basis - Google Patents

Liposomale abgabe von verbindungen auf vitamin-e- basis

Info

Publication number
ATE468109T1
ATE468109T1 AT02797447T AT02797447T ATE468109T1 AT E468109 T1 ATE468109 T1 AT E468109T1 AT 02797447 T AT02797447 T AT 02797447T AT 02797447 T AT02797447 T AT 02797447T AT E468109 T1 ATE468109 T1 AT E468109T1
Authority
AT
Austria
Prior art keywords
vitamin
based compounds
liposomal delivery
hydrogen
vesicle
Prior art date
Application number
AT02797447T
Other languages
English (en)
Inventor
Bob Sanders
Kimberly Kline
Karla Lawson
Marla Menchaca
J Knight
Clyde Wellen
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE468109T1 publication Critical patent/ATE468109T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02797447T 2001-12-19 2002-12-19 Liposomale abgabe von verbindungen auf vitamin-e- basis ATE468109T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34215601P 2001-12-19 2001-12-19
US40680702P 2002-08-29 2002-08-29
US41860202P 2002-10-15 2002-10-15
PCT/US2002/040846 WO2003053407A1 (en) 2001-12-19 2002-12-19 Liposomal delivery of vitamin e based compounds

Publications (1)

Publication Number Publication Date
ATE468109T1 true ATE468109T1 (de) 2010-06-15

Family

ID=27407497

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02797447T ATE468109T1 (de) 2001-12-19 2002-12-19 Liposomale abgabe von verbindungen auf vitamin-e- basis

Country Status (12)

Country Link
EP (1) EP1463487B1 (de)
JP (1) JP2005526705A (de)
KR (1) KR101013426B1 (de)
CN (1) CN100515497C (de)
AT (1) ATE468109T1 (de)
AU (1) AU2002361812B2 (de)
CA (1) CA2470920C (de)
DE (1) DE60236456D1 (de)
DK (1) DK1463487T3 (de)
IL (2) IL162614A0 (de)
NZ (1) NZ533565A (de)
WO (1) WO2003053407A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US8101199B2 (en) 2003-10-21 2012-01-24 Celonova Biosciences, Inc. Des-methyl-tocopherol therapy for restenosis prevention
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
CA2599424A1 (en) * 2005-03-03 2006-09-08 Vital Health Sciences Pty Ltd Compounds having anti-cancer properties
KR100884570B1 (ko) * 2005-03-07 2009-02-18 순천향대학교 산학협력단 미강 내 토코트리에놀의 대량생산방법 및 이를 이용한 고기능성 토코트리에놀 제제
NZ565049A (en) 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
MY154376A (en) * 2006-02-13 2015-06-15 Malaysian Palm Oil Board Mpob A transdermal fluid
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
AU2008210207B2 (en) * 2007-02-01 2014-05-15 Med-Life Discoveries Lp Methods for the diagnosis of ovarian cancer health states and risk of ovarian cancer health states
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
EP2552486B1 (de) 2010-03-30 2020-08-12 Phosphagenics Limited Pflaster für transdermale verabreichung
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
US8816071B2 (en) 2011-12-02 2014-08-26 First Tech International Limited Tocotrienol derivatives and associated methods
EP3041831B1 (de) * 2013-09-06 2019-10-23 Research Development Foundation Alpha-tea-salzformen: zusammensetzungen und verwendungen zur behandlung von krankheiten
KR101629370B1 (ko) * 2014-05-14 2016-06-14 대한민국 토코트리에놀 생합성 형질전환 벼를 포함하는 전립선암 예방 또는 치료용 조성물
MY197126A (en) * 2015-01-23 2023-05-26 Malaysian Palm Oil Board Nanocarrier delivery system for hydrophobic substances
CA2991868C (en) * 2015-07-31 2025-05-27 Immunewalk Therapeutics, Inc. PROTEIN 2 CONTAINING THE MOTILE SPERM DOMAIN AND CANCER
EP3328408B1 (de) 2015-07-31 2020-10-07 Vascular Biogenics Ltd. Bewegliche spermadomäne mit protein 2 und entzündungen
CN114712308A (zh) 2015-12-09 2022-07-08 磷肌酸有限公司 药物制剂
CN108175861A (zh) * 2016-12-08 2018-06-19 暨南大学 一种抗肿瘤小核酸药物的递送系统及其应用
EP3558903B1 (de) 2016-12-21 2024-07-03 Avecho Biotechnology Limited Verfahren zur phosphorylierung eines komplexen alkohols
WO2022053985A1 (en) 2020-09-10 2022-03-17 Vascular Biogenics Ltd. Motile sperm domain containing protein 2 antibodies and methods of use thereof
CN112915105B (zh) * 2021-03-12 2024-07-19 上海市第六人民医院 间充质干细胞分泌的小细胞外囊泡在制备治疗cp/cpps的药物上的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
DE3686025T2 (de) * 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
US4797285A (en) * 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
JP2532709Y2 (ja) * 1989-04-20 1997-04-16 株式会社リコー プラスチックレンズの静電防止装置
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
CN1096194A (zh) * 1993-06-07 1994-12-14 北京和德实业公司 包埋维生素的卵磷脂脂质体的化妆品及其制法
ES2072223B1 (es) * 1993-11-25 1996-03-16 Lipotec Sa Liposomas encapsulando doxorubicina.
US5997899A (en) * 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6472432B1 (en) * 1997-11-17 2002-10-29 Nicholas V. Perricone Treatment of rosacea using lipoic acid
JP2002526446A (ja) * 1998-09-23 2002-08-20 リサーチ ディベロップメント ファンデーション トロフェロール、トコトリエノール、その他のクロマン及び側鎖誘導体、並びにそれらの利用
MXPA01011981A (es) * 1999-05-24 2003-09-04 Sonus Pharma Inc Vehiculo de emulsion para farmacos poco solubles.
KR20020059415A (ko) * 1999-09-27 2002-07-12 스티븐 씨. 큐웨이 토콜-가용성 치료요법제

Also Published As

Publication number Publication date
CN100515497C (zh) 2009-07-22
DE60236456D1 (de) 2010-07-01
EP1463487B1 (de) 2010-05-19
CA2470920A1 (en) 2003-07-03
DK1463487T3 (da) 2010-08-23
AU2002361812B2 (en) 2007-11-08
KR20040079911A (ko) 2004-09-16
IL162614A (en) 2013-12-31
EP1463487A1 (de) 2004-10-06
EP1463487A4 (de) 2007-01-03
CA2470920C (en) 2013-04-02
WO2003053407A1 (en) 2003-07-03
IL162614A0 (en) 2005-11-20
CN1617711A (zh) 2005-05-18
NZ533565A (en) 2006-11-30
JP2005526705A (ja) 2005-09-08
AU2002361812A1 (en) 2003-07-09
KR101013426B1 (ko) 2011-02-14

Similar Documents

Publication Publication Date Title
ATE468109T1 (de) Liposomale abgabe von verbindungen auf vitamin-e- basis
YU31303A (sh) Jedinjenja imidazola sa pripojenim arilom ili heteroarilom kao anti-inflamatorni i analgetički agensi
ATE334973T1 (de) Chinazolinverbindungen
UA70958C2 (uk) Спосіб лікування захворювання, пов'язаного з порушенням метаболізму естрогену (варіанти)
ES2059408T3 (es) Un proceso para la preparacion de un compuesto.
DK0707591T3 (da) Methylphosphonsyreestere, fremgangsmåde til deres fremstilling samt deres anvendelse
KR850000462A (ko) [[비스(아릴)메틸렌]-1-피페리디닐]알킬-피리미딘온의 제조방법
DE69705480D1 (de) Verwendung von Oestrogenagonisten und -antagonisten zur Herstellung eines Medikaments zur Behandlung von Atherosklerose, unabhängig von Lipidsenkung
HUT77627A (hu) 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
CY1111909T1 (el) Παραγωγα [[2-(αμινο-3,4-διοξο-1-κυκλοβουτεν-1-υλ)amino] αλκυλ]-οξεος για τη θεραπεια του πονου
ES2052504T3 (es) Derivado de difenilmetano, compuesto farmaceutico y su utilizacion.
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
EA200000948A1 (ru) Новые полициклические азаиндолы, способ их получения и фармацевтические композиции, содержащие их
ATE223915T1 (de) Neue heterozyklische chemie
UY25807A1 (es) Caprolactamas sustituidas, composiciones farmacéuticas que las contienen, y su uso en el tratamiento de tumores.
ATE273979T1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
ATE243202T1 (de) Neue antivirale, homocarbozklische nukleosidderivate von substituierten pyrimidindionen, verfahren zu ihrer herstellung und zusammensetzungen, die diese als aktiven bestandteil enthalten
ATE215934T1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
ATE267832T1 (de) Substanz gm-95, verfahren zu ihrer herstellung und ihre verwendung
MY113529A (en) New derivatives of imidazole n- benzyldioxole,processes for their preparation, their use as medicaments and pharmaceutical compositions containing them
ATE278403T1 (de) Verfahren zur inhibierung von katarakten
ES8707939A1 (es) Procedimiento para preparar derivados de n-carboxialquil-2--oxo-3-diaril-5,6-triazinas
TH40676A (th) อนุพันธ์เททราไฮโดรอิมิดาโซ [2,1-เอ] ไอโซควิโนลิน

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties